August 2012
-
Nanoform, which recently announced construction of a new GMP manufacturing facility in Helsinki, has announced the appointment of Niklas Sandler as Chief Technology Officer. Sandler was most recently Vice Rector responsible for Research Affairs and… Read more . . .
-
Glenmark Pharmaceuticals will receive an upfront payment, milestones, and royalties from Yuhan Corporation as part of a deal that gives Yuhan rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal… Read more . . .
-
According to Verona Pharma, the World Health Organization (WHO) has approved the name “ensifentrine” as the international non-proprietary name for the company’s RPL554 inhaled PDE3/PDE4 inhibitor, which is in development as both an MDI and… Read more . . .
-
Insys Therapeutics said that a dose finding study of its epinephrine nasal spray that enrolled 49 healthy volunteers demonstrated that one of two doses of the nasal spray tested had a PK profile comparable to… Read more . . .
-
Evoke Pharma said that it has signed a deal with Novos Growth Partners (NGP) for commercialization of its Gimoti metoclopramide nasal spray for the treatment of acute and recurrent diabetic gastroparesis in adult women. Evoke’s… Read more . . .
-
Verona Pharma, which is developing an inhaled PDE3/PDE4 inhibitor, has named Kathleen Rickard as Chief Medical Officer and Tara Rheault as VP of Research and Development Operations and Global Project Management. Rickard has previously served… Read more . . .
-
Liquidia Technologies has announced interim data from the Phase 3 INSPIRE trial of its LIQ861 DPI treprostinil for the treatment of pulmonary arterial hypertension demonstrating that LIQ861 was well-tolerated at doses of up to about… Read more . . .
-
Finnish nanotechnology company Nanoform has named Gonçalo Rebelo de Andrade, former Hovione Business Development Manager for inhalation and respiratory product development, as Chief of Business Operations. The company recently announced that it is building a… Read more . . .
-
Orexo has announced results from a PK study of its OX124 naloxone nasal spray in 20 healthy volunteers that compared 4 development formulations of OX124 to Narcan naloxone nasal spray. According to the company, all… Read more . . .
-
Impel NeuroPharma has announced results from a Phase 1 PK trial of INP105 intranasal olanzapine demonstrating that the intranasal formulation achieved Tmax two times faster than Zyprexa intramuscular olanzapine and ten times faster than Zyprexa… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.